[B-cell-depleting antibodies in skin diseases]

Basic insight into immune mechanisms, particularly the role and function of various immune cells and proinflammatory cytokines in the etiopathogenesis of inflammatory dermatoses and autoimmune skin disorders, has made possible the development of novel therapeutic strategies. Because of their properties as antigen presenting cells and progenitors of autoantibody-secreting plasma cells, B cells have a major impact in different autoimmune diseases and represent an important therapeutic target. The remarkable clinical improvement seen in patients with rheumatoid arthritis after treatment with the monoclonal anti-CD20 antibody, rituximab, has strongly augmented the interest in B-cell-targeted therapies in different autoimmune diseases. Future clinical and immunological investigations are mandatory to precisely define the contribution of impaired B-cell function in development and progression of autoimmune mediated skin disorders.